TD Asset Management Inc Reduces Stock Holdings in Guardant Health, Inc. $GH

Posted by George Bondi on Jun 8th, 2026

TD Asset Management Inc lowered its position in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 4.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 181,048 shares of the company’s stock after selling 7,762 shares during the period. TD Asset Management Inc’s holdings in Guardant Health were worth $18,492,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. AQR Capital Management LLC increased its position in Guardant Health by 56.5% during the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after purchasing an additional 25,831 shares in the last quarter. Empowered Funds LLC purchased a new stake in Guardant Health during the 1st quarter worth about $274,000. Sei Investments Co. increased its position in Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after purchasing an additional 10,538 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after purchasing an additional 54,284 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Guardant Health by 56.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock worth $5,800,000 after purchasing an additional 40,209 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on GH. Wells Fargo & Company lifted their price objective on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Wolfe Research began coverage on Guardant Health in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price objective for the company. BTIG Research set a $160.00 price objective on Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, May 27th. Stifel Nicolaus lifted their price objective on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Finally, TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $137.80.

Read Our Latest Stock Analysis on Guardant Health

Insider Transactions at Guardant Health

In other Guardant Health news, insider Chris Freeman sold 24,406 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $118.67, for a total value of $2,896,260.02. Following the sale, the insider directly owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. This trade represents a 28.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John G. Saia sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $125.08, for a total value of $1,250,800.00. Following the completion of the sale, the insider directly owned 35,950 shares in the company, valued at approximately $4,496,626. The trade was a 21.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 350,238 shares of company stock worth $38,538,372 in the last quarter. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $125.61 on Monday. The stock’s 50-day moving average price is $99.39 and its two-hundred day moving average price is $101.12. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $134.28. The firm has a market cap of $16.66 billion, a price-to-earnings ratio of -37.05 and a beta of 1.61.

Guardant Health Profile

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.